

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use Menactra® safely and effectively. See full prescribing information for Menactra vaccine.

Menactra®, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Solution for Intramuscular Injection

Initial U.S. Approval: 2005

### RECENT MAJOR CHANGES

Dosage and Administration (2) [8/2014]  
Warnings and Precautions (5) [8/2014]

### INDICATIONS AND USAGE

Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by *N meningitidis* serogroups A, C, Y and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent *N meningitidis* serogroup B disease. (1)

### DOSAGE AND ADMINISTRATION

A 0.5 mL dose for intramuscular injection. (2)

Primary Vaccination:

- Children 9 through 23 months of age: Two doses, three months apart.
- Individuals 2 through 55 years of age: A single dose.

Booster Vaccination:

- A single booster dose may be given to individuals 15 through 55 years of age at continued risk for meningococcal disease, if at least 4 years have elapsed since the prior dose.

### DOSAGE FORMS AND STRENGTHS

Solution supplied in 0.5 mL single-dose vials (3)

### CONTRAINDICATIONS

- Severe allergic reaction (eg, anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide-, diphtheria toxoid- or CRM<sub>197</sub>-containing vaccine, or to any component of Menactra vaccine. (4)

### WARNINGS AND PRECAUTIONS

- Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra vaccine. The decision to give Menactra vaccine should take into account the potential benefits and risks. (5.1)

### ADVERSE REACTIONS

- Common (≥10%) solicited adverse events in infants and toddlers 9 and 12 months of age were injection site tenderness, erythema, and swelling; irritability, abnormal crying, drowsiness, appetite loss, vomiting, and fever. (6)
- Common (≥10%) solicited adverse events in individuals 2 through 55 years of age who received a single dose were injection site pain, redness, induration, and swelling; anorexia and diarrhea. Other common solicited adverse events were irritability and drowsiness (2-10 years of age), headache, fatigue, malaise, and arthralgia (11-55 years of age). (6)

To report SUSPECTED ADVERSE REACTIONS, contact Sanofi Pasteur Inc. at 1-800-822-2463 (1-800-VACCINE) or VAERS at 1-800-822-7967 or <http://vaers.hhs.gov>.

### DRUG INTERACTIONS

- Pneumococcal antibody responses to some serotypes in Pevnar (PCV7) were decreased following co-administration of Menactra vaccine and PCV7. (7.1)

### USE IN SPECIFIC POPULATIONS

- Safety and effectiveness of Menactra vaccine have not been established in children younger than 9 months of age, pregnant women, nursing mothers, and adults older than 55 years of age. (8.1, 8.3, 8.4, 8.5)
- A pregnancy registry is available. Contact Sanofi Pasteur Inc. at 1-800-822-2463. (8.1)

See 17 PATIENT\_COUNSELING\_INFORMATION.

Revised: August 2014

## FULL PRESCRIBING INFORMATION: CONTENTS\*

### 1 INDICATIONS AND USAGE

### 2 DOSAGE AND ADMINISTRATION

- 2.1 Preparation for Administration
- 2.2 Dose and Schedule

### 3 DOSAGE FORMS AND STRENGTHS

### 4 CONTRAINDICATIONS

### 5 WARNINGS AND PRECAUTIONS

- 5.1 Guillain-Barré Syndrome
- 5.2 Preventing and Managing Allergic Vaccine Reactions
- 5.3 Altered Immunocompetence
- 5.4 Limitations of Vaccine Effectiveness
- 5.5 Syncope

### 6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Post-Marketing Experience

### 7 DRUG INTERACTIONS

- 7.1 Concomitant Administration with Other Vaccines
- 7.2 Immunosuppressive Therapies

### 8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use

### 11 DESCRIPTION

### 12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action

### 13 NON-CLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

### 14 CLINICAL STUDIES

- 14.1 Efficacy
- 14.2 Immunogenicity
- 14.3 Concomitant Vaccine Administration

### 15 REFERENCES

### 16 HOW SUPPLIED/STORAGE AND HANDLING

- 16.1 How Supplied
- 16.2 Storage and Handling

### 17 PATIENT COUNSELING INFORMATION

\*Sections or subsections omitted from the full prescribing information are not listed.

1 **FULL PRESCRIBING INFORMATION:**

2 **1 INDICATIONS AND USAGE**

3 Menactra®, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid  
4 Conjugate Vaccine, is indicated for active immunization to prevent invasive meningococcal  
5 disease caused by *N meningitidis* serogroups A, C, Y and W-135. Menactra vaccine is approved  
6 for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent *N*  
7 *meningitidis* serogroup B disease.

8

9 **2 DOSAGE AND ADMINISTRATION**

10 **2.1 Preparation for Administration**

11 Menactra vaccine is a clear to slightly turbid solution. Parenteral drug products should be  
12 inspected visually for particulate matter and discoloration prior to administration, whenever  
13 solution and container permit. If any of these conditions exist, the vaccine should not be  
14 administered.

15

16 Withdraw the 0.5 mL dose of vaccine from the single-dose vial using a sterile needle and syringe.

17

18 **2.2 Dose and Schedule**

19 Menactra vaccine is administered as a 0.5 mL dose by intramuscular injection. Do not administer  
20 this product intravenously or subcutaneously.

21

22 ***Primary Vaccination:***

1 • In children 9 through 23 months of age, Menactra vaccine is given as a 2-dose series three  
2 months apart.

3 • Individuals 2 through 55 years of age, Menactra vaccine is given as a single dose.

4 ***Booster Vaccination:***

5 • A single booster dose may be given to individuals 15 through 55 years of age at continued risk  
6 for meningococcal disease, if at least 4 years have elapsed since the prior dose.

7

8 **3 DOSAGE FORMS AND STRENGTHS**

9 Menactra vaccine is a solution supplied in 0.5 mL single-dose vials. [See *Description (11)* for a  
10 complete listing of ingredients.]

11

12 **4 CONTRAINDICATIONS**

13 Severe allergic reaction (eg, anaphylaxis) after a previous dose of a meningococcal capsular  
14 polysaccharide-, diphtheria toxoid- or CRM<sub>197</sub>-containing vaccine, or to any component of  
15 Menactra vaccine [see *Description (11)*].

16

17 **5 WARNINGS AND PRECAUTIONS**

18 **5.1 Guillain-Barré Syndrome**

19 Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of  
20 GBS following receipt of Menactra vaccine. The decision to give Menactra vaccine should take  
21 into account the potential benefits and risks.

22

1 GBS has been reported in temporal relationship following administration of Menactra vaccine. (1)  
2 (2) The risk of GBS following Menactra vaccination was evaluated in a post-marketing  
3 retrospective cohort study [*Post-Marketing Experience (6.2)*].  
4

## 5 **5.2 Preventing and Managing Allergic Vaccine Reactions**

6 Prior to administration, the healthcare provider should review the immunization history for  
7 possible vaccine sensitivity and previous vaccination-related adverse reactions to allow an  
8 assessment of benefits and risks. Epinephrine and other appropriate agents used for the control of  
9 immediate allergic reactions must be immediately available should an acute anaphylactic reaction  
10 occur.  
11

## 12 **5.3 Altered Immunocompetence**

13 Immunocompromised persons, including individuals receiving immunosuppressant therapy, may  
14 have a diminished immune response to Menactra vaccine.  
15

## 16 **5.4 Limitations of Vaccine Effectiveness**

17 Menactra vaccine may not protect all recipients.  
18

## 19 **5.5 Syncope**

20 Syncope (fainting) has been reported following vaccination with Menactra vaccine. Procedures  
21 should be in place to prevent falling injury and manage syncopal reactions.  
22

## 6 ADVERSE REACTIONS

### 6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.

#### *Children 9 Through 12 Months of Age*

The safety of Menactra vaccine was evaluated in four clinical studies that enrolled 3721 participants who received Menactra vaccine at 9 and 12 months of age. At 12 months of age these children also received one or more other recommended vaccines [Measles, Mumps, Rubella and Varicella Virus Vaccine Live (MMRV) or Measles, Mumps, and Rubella Virus Vaccine (MMR) and Varicella Virus Vaccine Live (V) each manufactured by Merck & Co., Inc., Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM<sub>197</sub> Protein) manufactured by Wyeth Pharmaceuticals Inc. (PCV7), Hepatitis A Vaccine manufactured by Merck & Co., Inc. (HepA). A control group of 997 children was enrolled at 12 months of age and received two or more childhood vaccines [MMRV (or MMR+V), PCV7, HepA] at 12 months of age [see *Concomitant Vaccine Administration* (14.3)]. Three percent of individuals received MMR and V, instead of MMRV, at 12 months of age.

The primary safety study was a controlled trial that enrolled 1256 children who received Menactra vaccine at 9 and 12 months of age. At 12 months of age these children received MMRV (or MMR+V), PCV7 and HepA. A control group of 522 children received MMRV, PCV7 and HepA. Of the 1778 children, 78% of participants (Menactra vaccine, N=1056; control group, N=322)

1 were enrolled at United States (US) sites and 22% at a Chilean site. (Menactra vaccine, N=200;  
2 control group, N=200).

3

#### 4 *Individuals 2 Through 55 Years of Age*

5 The safety of Menactra vaccine was evaluated in eight clinical studies that enrolled 10,057  
6 participants aged 2-55 years who received Menactra vaccine and 5,266 participants who received  
7 Menomune® – A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-  
8 135 Combined. There were no substantive differences in demographic characteristics between the  
9 vaccine groups. Among Menactra vaccine recipients 2-55 years of age 24.0%, 16.2%, 40.4% and  
10 19.4% were in the 2-10, 11-14, 15-25 and 26-55-year age groups, respectively. Among  
11 Menomune – A/C/Y/W-135 vaccine recipients 2-55 years of age 42.3%, 9.3%, 30.0% and 18.5%  
12 were in the 2-10, 11-14, 15-25 and 26-55-year age groups, respectively. The three primary safety  
13 studies were randomized, active-controlled trials that enrolled participants 2-10 years of age  
14 (Menactra vaccine, N=1713; Menomune – A/C/Y/W-135 vaccine, N=1519), 11-18 years of age  
15 (Menactra vaccine, N=2270; Menomune – A/C/Y/W-135 vaccine, N=972) and 18-55 years of age  
16 (Menactra vaccine, N=1384; Menomune – A/C/Y/W-135 vaccine, N=1170), respectively. Of the  
17 3232 children 2-10 years of age, 68% of participants (Menactra vaccine, N=1164; Menomune –  
18 A/C/Y/W-135 vaccine, N=1031) were enrolled at US sites and 32% (Menactra vaccine, N=549;  
19 Menomune – A/C/Y/W-135 vaccine, N=488) of participants at a Chilean site. The median ages in  
20 the Chilean and US subpopulations were 5 and 6 years, respectively. All adolescents and adults  
21 were enrolled at US sites. As the route of administration differed for the two vaccines (Menactra  
22 vaccine given intramuscularly, Menomune – A/C/Y/W-135 vaccine given subcutaneously), study  
23 personnel collecting the safety data differed from personnel administering the vaccine.

1

2 ***Booster Vaccination Study***

3 In an open-label trial conducted in the US, 834 individuals were enrolled to receive a single dose  
4 of Menactra vaccine 4-6 years after a prior dose. The median age of participants was 17.1 years at  
5 the time of the booster dose.

6

7 ***Safety Evaluation***

8 Participants were monitored after each vaccination for 20 or 30 minutes for immediate reactions,  
9 depending on the study. Solicited injection site and systemic reactions were recorded in a diary  
10 card for 7 consecutive days after each vaccination. Participants were monitored for 28 days (30  
11 days for infants and toddlers) for unsolicited adverse events and for 6 months post-vaccination for  
12 visits to an emergency room, unexpected visits to an office physician, and serious adverse events.  
13 Unsolicited adverse event information was obtained either by telephone interview or at an interim  
14 clinic visit. Information regarding adverse events that occurred in the 6-month post-vaccination  
15 time period was obtained via a scripted telephone interview.

16

17 ***Serious Adverse Events in All Safety Studies***

18 Serious adverse events (SAEs) were reported during a 6-month time period following  
19 vaccinations in individuals 9 months through 55 years of age. In children who received Menactra  
20 vaccine at 9 months and at 12 months of age, SAEs occurred at a rate of 2.0% - 2.5%. In  
21 participants who received one or more childhood vaccine(s) (without co-administration of  
22 Menactra vaccine) at 12 months of age, SAEs occurred at a rate of 1.6% - 3.6%, depending on the  
23 number and type of vaccines received. In children 2-10 years of age, SAEs occurred at a rate of

1 0.6% following Menactra vaccine and at a rate of 0.7% following Menomune – A/C/Y/W-135  
2 vaccine. In adolescents 11 through 18 years of age and adults 18 years through 55 years of age,  
3 SAEs occurred at a rate of 1.0% following Menactra vaccine and at a rate of 1.3% following  
4 Menomune – A/C/Y/W-135 vaccine. In adolescents and adults, SAEs occurred at a rate of 1.3%  
5 following booster vaccination with Menactra vaccine.

6

7 *Solicited Adverse Events in the Primary Safety Studies*

8 The most frequently reported solicited injection site and systemic adverse reactions within 7 days  
9 following vaccination in children 9 months and 12 months of age ([Table 1](#)) were injection site  
10 tenderness and irritability.

11

12 The most frequently reported solicited injection site and systemic adverse reactions in US children  
13 aged 2-10 years of age ([Table 2](#)) were injection site pain and irritability. Diarrhea, drowsiness,  
14 and anorexia were also common.

15

16 The most commonly reported solicited injection site and systemic adverse reactions in  
17 adolescents, ages 11-18 years ([Table 3](#)), and adults, ages 18-55 years ([Table 4](#)), after a single dose  
18 were injection site pain, headache and fatigue. Except for redness in adults, injection site reactions  
19 were more frequently reported after Menactra vaccination than after Menomune – A/C/Y/W-135  
20 vaccination.

21



- 1 **Table 1: Percentage of US Participants Reporting Solicited Adverse Reactions Within 7**
- 2 **Days Following Vaccine Administration at 9 Months and 12 Months of Age**

Reaction	Menactra vaccine at 9 months of age			Menactra + PCV7 <sup>a</sup> + MMRV <sup>b</sup> + HepA <sup>c</sup> vaccines at 12 months of age			PCV7 <sup>a</sup> + MMRV <sup>b</sup> + HepA <sup>c</sup> vaccines at 12 months of age		
	N <sup>d</sup> =998 - 1002			N <sup>d</sup> =898 - 908			N <sup>d</sup> =302 - 307		
	Any	Grade 2	Grade 3	Any	Grade 2	Grade 3	Any	Grade 2	Grade 3
<b>Local/Injection Site</b>									
<b>Tenderness<sup>e</sup></b>									
Menactra Site	37.4	4.3	0.6	48.5	7.5	1.3	-	-	-
PCV7 Site	-	-	-	45.6	9.4	1.6	45.7	8.3	0.3
MMRV Site	-	-	-	38.9	7.1	1.0	43.0	5.2	0.0
HepA Site	-	-	-	43.4	8.7	1.4	40.9	4.6	0.3
<b>Erythema<sup>f</sup></b>									
Menactra Site	30.2	2.5	0.3	30.1	1.3	0.1	-	-	-
PCV7 Site	-	-	-	29.4	2.6	0.2	32.6	3.0	0.7
MMRV Site	-	-	-	22.5	0.9	0.3	33.2	5.9	0.0
HepA Site	-	-	-	25.1	1.1	0.0	26.6	0.7	0.0
<b>Swelling<sup>f</sup></b>									
Menactra Site	16.8	0.9	0.2	16.2	0.9	0.1	-	-	-
PCV7 Site	-	-	-	19.5	1.3	0.4	16.6	1.3	0.7
MMRV Site	-	-	-	12.1	0.4	0.1	14.1	0.3	0.0
HepA Site	-	-	-	16.4	0.7	0.2	13.5	0.0	0.3
<b>Systemic</b>									
Irritability <sup>g</sup>	56.8	23.1	2.9	62.1	25.7	3.7	64.8	28.7	4.2
Abnormal crying <sup>h</sup>	33.3	8.3	2.0	40.0	11.5	2.4	39.4	10.1	0.7
Drowsiness <sup>i</sup>	30.2	3.5	0.7	39.8	5.3	1.1	39.1	5.2	0.7
Appetite loss <sup>j</sup>	30.2	7.1	1.2	35.7	7.6	2.6	31.9	6.5	0.7
Vomiting <sup>k</sup>	14.1	4.6	0.3	11.0	4.4	0.2	9.8	2.0	0.0
Fever <sup>l</sup>	12.2	4.5	1.1	24.5	11.9	2.2	21.8	7.3	2.6

3 <sup>a</sup>PCV7 (Prevnar®) = Pneumococcal 7-valent Conjugate Vaccine

4 <sup>b</sup>MMRV (ProQuad®) = Measles, Mumps, Rubella and Varicella Virus Vaccine Live

- 1 <sup>c</sup> HepA (VAQTA®) = Hepatitis A Vaccine, Inactivated
- 2 <sup>d</sup> N = The number of subjects with available data.
- 3 <sup>e</sup> Grade 2: cries and protests when injection site is touched, Grade 3: cries when injected limb is moved, or the
- 4 movement of the injected limb is reduced.
- 5 <sup>f</sup> Grade 2:  $\geq 1.0$  inches to  $< 2.0$  inches, Grade 3:  $\geq 2.0$  inches.
- 6 <sup>g</sup> Grade 2: requires increased attention, Grade 3: inconsolable.
- 7 <sup>h</sup> Grade 2: 1 to 3 hours, Grade 3:  $> 3$  hours.
- 8 <sup>i</sup> Grade 2: not interested in surroundings or did not wake up for a feed/meal, Grade 3: sleeping most of the time or
- 9 difficult to wake up.
- 10 <sup>j</sup> Grade 2: missed 1 or 2 feeds/meals completely, Grade 3: refuses  $\geq 3$  feeds/meals or refuses most feeds/meals.
- 11 <sup>k</sup> Grade 2: 2 to 5 episodes per 24 hours, Grade 3:  $\geq 6$  episodes per 24 hours or requiring parenteral hydration.
- 12 <sup>l</sup> Grade 2:  $> 38.5^{\circ}\text{C}$  to  $\leq 39.5^{\circ}\text{C}$ , Grade 3:  $> 39.5^{\circ}\text{C}$ .
- 13
- 14

1 **Table 2: Percentage of US Participants 2 Years Through 10 Years of Age Reporting**  
 2 **Solicited Adverse Reactions Within 7 Days Following Vaccine Administration**

Reaction	Menactra vaccine N <sup>a</sup> =1156 - 1157			Menomune – A/C/Y/W-135 vaccine N <sup>a</sup> =1027		
	Any	Grade 2	Grade 3	Any	Grade 2	Grade 3
<b>Local/Injection Site</b>						
Pain <sup>b</sup>	45.0	4.9	0.3	26.1	2.5	0.0
Redness <sup>c</sup>	21.8	4.6	3.9	7.9	0.5	0.0
Induration <sup>c</sup>	18.9	3.4	1.4	4.2	0.6	0.0
Swelling <sup>c</sup>	17.4	3.9	1.9	2.8	0.3	0.0
<b>Systemic</b>						
Irritability <sup>d</sup>	12.4	3.0	0.3	12.2	2.6	0.6
Diarrhea <sup>e</sup>	11.1	2.1	0.2	11.8	2.5	0.3
Drowsiness <sup>f</sup>	10.8	2.7	0.3	11.2	2.5	0.5
Anorexia <sup>g</sup>	8.2	1.7	0.4	8.7	1.3	0.8
Arthralgia <sup>h</sup>	6.8	0.5	0.2	5.3	0.7	0.0
Fever <sup>i</sup>	5.2	1.7	0.3	5.2	1.7	0.2
Rash <sup>j</sup>	3.4	-	-	3.0	-	-
Vomiting <sup>k</sup>	3.0	0.7	0.3	2.7	0.7	0.6
Seizure <sup>j</sup>	0.0	-	-	0.0	-	-

3 <sup>a</sup> N = The total number of subjects reporting at least one solicited reaction. The median age of participants was 6 years  
 4 in both vaccine groups.

5 <sup>b</sup> Grade 2: interferes with normal activities, Grade 3: disabling, unwilling to move arm.

6 <sup>c</sup> Grade 2: 1.0-2.0 inches, Grade 3: >2.0 inches.

7 <sup>d</sup> Grade 2: 1-3 hours duration, Grade 3: >3 hours duration.

8 <sup>e</sup> Grade 2: 3-4 episodes, Grade 3: ≥5 episodes.

9 <sup>f</sup> Grade 2: interferes with normal activities, Grade 3: disabling, unwilling to engage in play or interact with others.

- 1 <sup>g</sup> Grade 2: skipped 2 meals, Grade 3: skipped  $\geq 3$  meals.
- 2 <sup>h</sup> Grade 2: decreased range of motion due to pain or discomfort, Grade 3: unable to move major joints due to pain.
- 3 <sup>i</sup> Oral equivalent temperature; Grade 2: 38.4°C to 39.4°C, Grade 3:  $\geq 39.5^\circ\text{C}$ .
- 4 <sup>j</sup> These solicited adverse events were reported as present or absent only.
- 5 <sup>k</sup> Grade 2: 2 episodes, Grade 3:  $\geq 3$  episodes.
- 6 Note: During the study Grade 1, Grade 2, and Grade 3 were collected as Mild, Moderate, and Severe respectively.
- 7
- 8

1 **Table 3: Percentage of Participants 11 Years Through 18 Years of Age Reporting Solicited**  
 2 **Adverse Reactions Within 7 Days Following Vaccine Administration With a Single Dose**

Reaction	Menactra vaccine N <sup>a</sup> =2264 - 2265			Menomune – A/C/Y/W-135 vaccine N <sup>a</sup> =970		
	Any	Grade 2	Grade 3	Any	Grade 2	Grade 3
<b>Local/Injection Site</b>						
Pain <sup>b</sup>	59.2 <sup>c</sup>	12.8 <sup>c</sup>	0.3	28.7	2.6	0.0
Induration <sup>d</sup>	15.7 <sup>c</sup>	2.5 <sup>c</sup>	0.3	5.2	0.5	0.0
Redness <sup>d</sup>	10.9 <sup>c</sup>	1.6 <sup>c</sup>	0.6 <sup>c</sup>	5.7	0.4	0.0
Swelling <sup>d</sup>	10.8 <sup>c</sup>	1.9 <sup>c</sup>	0.5 <sup>c</sup>	3.6	0.3	0.0
<b>Systemic</b>						
Headache <sup>e</sup>	35.6 <sup>c</sup>	9.6 <sup>c</sup>	1.1	29.3	6.5	0.4
Fatigue <sup>e</sup>	30.0 <sup>c</sup>	7.5	1.1 <sup>c</sup>	25.1	6.2	0.2
Malaise <sup>e</sup>	21.9 <sup>c</sup>	5.8 <sup>c</sup>	1.1	16.8	3.4	0.4
Arthralgia <sup>e</sup>	17.4 <sup>c</sup>	3.6 <sup>c</sup>	0.4	10.2	2.1	0.1
Diarrhea <sup>f</sup>	12.0	1.6	0.3	10.2	1.3	0.0
Anorexia <sup>g</sup>	10.7 <sup>c</sup>	2.0	0.3	7.7	1.1	0.2
Chills <sup>e</sup>	7.0 <sup>c</sup>	1.7 <sup>c</sup>	0.2	3.5	0.4	0.1
Fever <sup>h</sup>	5.1 <sup>c</sup>	0.6	0.0	3.0	0.3	0.1
Vomiting <sup>i</sup>	1.9	0.4	0.3	1.4	0.5	0.3
Rash <sup>j</sup>	1.6	-	-	1.4	-	-
Seizure <sup>j</sup>	0.0	-	-	0.0	-	-

3 <sup>a</sup>N = The number of subjects with available data.

4 <sup>b</sup>Grade 2: interferes with or limits usual arm movement, Grade 3: disabling, unable to move arm.

5 <sup>c</sup>Denotes  $p < 0.05$  level of significance. The  $p$ -values were calculated for each category and severity using Chi Square  
 6 test.

7 <sup>d</sup>Grade 2: 1.0-2.0 inches, Grade 3: >2.0 inches.

8 <sup>e</sup>Grade 2: interferes with normal activities, Grade 3: requiring bed rest.

- 1 <sup>f</sup> Grade 2: 3-4 episodes, Grade 3:  $\geq 5$  episodes.
- 2 <sup>g</sup> Grade 2: skipped 2 meals, Grade 3: skipped  $\geq 3$  meals.
- 3 <sup>h</sup> Oral equivalent temperature; Grade 2: 38.5°C to 39.4°C, Grade 3:  $\geq 39.5^\circ\text{C}$ .
- 4 <sup>i</sup> Grade 2: 2 episodes, Grade 3:  $\geq 3$  episodes.
- 5 <sup>j</sup> These solicited adverse events were reported as present or absent only.
- 6 Note: During the study Grade 1, Grade 2, and Grade 3 were collected as Mild, Moderate, and Severe respectively.
- 7
- 8

1 **Table 4: Percentage of Participants 18 Years Through 55 Years of Age Reporting Solicited**  
 2 **Adverse Reactions Within 7 Days Following Vaccine Administration With a Single Dose**

Reaction	Menactra vaccine N <sup>a</sup> =1371			Menomune – A/C/Y/W-135 vaccine N <sup>a</sup> =1159		
	Any	Grade 2	Grade 3	Any	Grade 2	Grade 3
<b>Local/Injection Site</b>						
Pain <sup>b</sup>	53.9 <sup>c</sup>	11.3 <sup>c</sup>	0.2	48.1	3.3	0.1
Induration <sup>d</sup>	17.1 <sup>c</sup>	3.4 <sup>c</sup>	0.7 <sup>c</sup>	11.0	1.0	0.0
Redness <sup>d</sup>	14.4	2.9	1.1 <sup>c</sup>	16.0	1.9	0.1
Swelling <sup>d</sup>	12.6 <sup>c</sup>	2.3 <sup>c</sup>	0.9 <sup>c</sup>	7.6	0.7	0.0
<b>Systemic</b>						
Headache <sup>e</sup>	41.4	10.1	1.2	41.8	8.9	0.9
Fatigue <sup>e</sup>	34.7	8.3	0.9	32.3	6.6	0.4
Malaise <sup>e</sup>	23.6	6.6 <sup>c</sup>	1.1	22.3	4.7	0.9
Arthralgia <sup>e</sup>	19.8 <sup>c</sup>	4.7 <sup>c</sup>	0.3	16.0	2.6	0.1
Diarrhea <sup>f</sup>	16.0	2.6	0.4	14.0	2.9	0.3
Anorexia <sup>g</sup>	11.8	2.3	0.4	9.9	1.6	0.4
Chills <sup>e</sup>	9.7 <sup>c</sup>	2.1 <sup>c</sup>	0.6 <sup>c</sup>	5.6	1.0	0.0
Vomiting <sup>h</sup>	2.3	0.4	0.2	1.5	0.2	0.4
Fever <sup>i</sup>	1.5 <sup>c</sup>	0.3	0.0	0.5	0.1	0.0
Rash <sup>j</sup>	1.4	-	-	0.8	-	-
Seizure <sup>j</sup>	0.0	-	-	0.0	-	-

3 <sup>a</sup>N = The number of subjects with available data.

4 <sup>b</sup>Grade 2: interferes with or limits usual arm movement, Grade 3: disabling, unable to move arm.

5 <sup>c</sup> Denotes  $p < 0.05$  level of significance. The  $p$ -values were calculated for each category and severity using Chi Square  
 6 test.

7 <sup>d</sup>Grade 2: 1.0-2.0 inches, Grade 3: >2.0 inches.

8 <sup>e</sup>Grade 2: interferes with normal activities, Grade 3: requiring bed rest.

9 <sup>f</sup>Grade 2: 3-4 episodes, Grade 3: ≥5 episodes.

1 <sup>g</sup> Grade 2: skipped 2 meals, Grade 3: skipped  $\geq 3$  meals.

2 <sup>h</sup> Grade 2: 2 episodes, Grade 3:  $\geq 3$  episodes.

3 <sup>i</sup> Oral equivalent temperature; Grade 2: 39.0°C to 39.9°C, Grade 3:  $\geq 40.0$ °C.

4 <sup>j</sup> These solicited adverse events were reported as present or absent only.

5 Note: During the study Grade 1, Grade 2, and Grade 3 were collected as Mild, Moderate, and Severe respectively.

6

### 7 ***Solicited Adverse Events in a Booster Vaccination Study***

8 [For a description of the study design and number of participants, see *Clinical Trials Experience*,  
9 *Booster Vaccination Study (6.1)*] The most common solicited injection site and systemic reactions  
10 within 7 days of vaccination were pain (60.2%) and myalgia (42.8%), respectively. Overall rates  
11 of solicited injection site reactions and solicited systemic reactions were similar to those observed  
12 in adolescents and adults after a single Menactra dose. The majority of solicited reactions were  
13 Grade 1 or 2 and resolved within 3 days.

14

### 15 ***Adverse Events in Concomitant Vaccine Studies***

#### 16 **Solicited Injection Site and Systemic Reactions when Given with Routine Pediatric Vaccines**

17 For a description of the study design and number of participants [see *Clinical Trials Experience*  
18 *(6.1)*, *Concomitant Vaccine Administration (14.3)*]. In the primary safety study, 1378 US children  
19 were enrolled to receive Menactra vaccine alone at 9 months of age and Menactra vaccine plus  
20 one or more other routinely administered vaccines (MMRV, PCV7 and HepA) at 12 months of  
21 age (N=961). Another group of children received two or more routinely administered vaccines  
22 (MMRV, PCV7 and HepA) (control group, n=321) at 12 months of age. The frequency of  
23 occurrence of solicited adverse events is presented in [Table 1](#). Participants who received Menactra



1 vaccine and the concomitant vaccines at 12 months of age described above reported similar  
2 frequencies of tenderness, redness and swelling at the Menactra vaccine injection site and at the  
3 concomitant vaccine injection sites. Tenderness was the most frequent injection site reaction  
4 (48%, 39%, 46% and 43% at the Menactra vaccine, MMRV, PCV7 and HepA sites, respectively).  
5 Irritability was the most frequent systemic reaction, reported in 62% of recipients of Menactra  
6 vaccine plus concomitant vaccines, and 65% of the control group. [See *Concomitant Vaccine*  
7 *Administration (14.3)*].

8

9 **Solicited Injection site and Systemic Reactions when Given with Tetanus and Diphtheria**  
10 **Toxoid Adsorbed Vaccine**

11 In a clinical study, rates of local and systemic reactions after Menactra vaccine and Tetanus and  
12 Diphtheria Toxoid Adsorbed (Td) vaccine manufactured by Sanofi Pasteur Inc. were compared  
13 [see *Drug Interactions (7)*, and *Concomitant Vaccine Administration (14.3)* for study description].  
14 Injection site pain was reported more frequently after Td vaccination than after Menactra  
15 vaccination (71% versus 53%). The overall rate of systemic adverse events was higher when  
16 Menactra and Td vaccines were given concomitantly than when Menactra vaccine was  
17 administered 28 days after Td (59% versus 36%). In both groups, the most common reactions  
18 were headache (Menactra vaccine + Td, 36%; Td + Placebo, 34%; Menactra vaccine alone, 22%)  
19 and fatigue (Menactra vaccine + Td, 32%; Td + Placebo, 29%; Menactra vaccine alone, 17%).  
20 Fever  $\geq 40.0^{\circ}\text{C}$  occurred at  $\leq 0.5\%$  in all groups.

21

22 **Solicited Injection site and Systemic Reactions when Given with Typhoid Vi Polysaccharide**  
23 **Vaccine**

1 In a clinical study, rates of local and systemic reactions after Menactra vaccine and Typhoid Vi  
2 Polysaccharide Vaccine, produced by Sanofi Pasteur SA were compared [see *Drug Interactions*  
3 (7) and *Concomitant Vaccine Administration (14.3)*] for a description of the concomitantly  
4 administered vaccine, study design and number of participants. More participants experienced  
5 pain after Typhoid vaccination than after Menactra vaccination (Typhoid + Placebo, 76% versus  
6 Menactra vaccine + Typhoid, 47%). The majority (70%-77%) of injection site solicited reactions  
7 for both groups at either injection site were reported as Grade 1 and resolved within 3 days post-  
8 vaccination. In both groups, the most common systemic reaction was headache (Menactra vaccine  
9 + Typhoid, 41%; Typhoid + Placebo, 42%; Menactra vaccine alone, 33%) and fatigue (Menactra  
10 vaccine + Typhoid, 38%; Typhoid + Placebo, 35%; Menactra vaccine alone, 27%). Fever  $\geq 40.0^{\circ}\text{C}$   
11 and seizures were not reported in either group.

12

## 13 **6.2 Post-Marketing Experience**

14 In addition to reports in clinical trials, worldwide voluntary adverse events reports received since  
15 market introduction of Menactra vaccine are listed below. This list includes serious events and/or  
16 events which were included based on severity, frequency of reporting or a plausible causal  
17 connection to Menactra vaccine. Because these events were reported voluntarily from a  
18 population of uncertain size, it is not possible to reliably estimate their frequency or establish a  
19 causal relationship to vaccination.

- 20 • *Immune System Disorders*

21 Hypersensitivity reactions such as anaphylaxis/anaphylactic reaction, wheezing, difficulty  
22 breathing, upper airway swelling, urticaria, erythema, pruritus, hypotension

23

1       • *Nervous System Disorders*

2           Guillain-Barré syndrome, paraesthesia, vasovagal syncope, dizziness, convulsion, facial  
3           palsy, acute disseminated encephalomyelitis, transverse myelitis

4  
5       • *Musculoskeletal and Connective Tissue Disorders*

6           Myalgia

7  
8       ***Post-marketing Safety Study***

9       The risk of GBS following receipt of Menactra vaccine was evaluated in a US retrospective  
10       cohort study using healthcare claims data from 9,578,688 individuals 11 through 18 years of age,  
11       of whom 1,431,906 (15%) received Menactra vaccine. Of 72 medical chart-confirmed GBS cases,  
12       none had received Menactra vaccine within 42 days prior to symptom onset. An additional 129  
13       potential cases of GBS could not be confirmed or excluded due to absent or insufficient medical  
14       chart information. In an analysis that took into account the missing data, estimates of the  
15       attributable risk of GBS ranged from 0 to 5 additional cases of GBS per 1,000,000 vaccinees  
16       within the 6-week period following vaccination.

17  
18       **7 DRUG INTERACTIONS**

19       **7.1 Concomitant Administration with Other Vaccines**

20       Menactra vaccine was concomitantly administered with Typhim Vi® [Typhoid Vi Polysaccharide  
21       Vaccine] (Typhoid) and Tetanus and Diphtheria Toxoids Adsorbed, For Adult Use (Td), in  
22       individuals 18 through 55 and 11 through 17 years of age, respectively. In children younger than 2

1 years of age, Menactra was co-administered with one or more of the following vaccines: PCV7,  
2 MMR, V, MMRV, or HepA [see *Clinical Studies (14)* and *Adverse Reactions (6)*].

3

4 Data are not available to assess the safety and immunogenicity of Menactra and DTaP-containing  
5 vaccines when administered concomitantly at 15 months of age.

6

7 Pneumococcal antibody responses to some serotypes in PCV7 were decreased following co-  
8 administration of Menactra vaccine and PCV7 [see *Concomitant Vaccine Administration (14.3)*].

9

10 Do not mix Menactra vaccine with other vaccines in the same syringe. When Menactra vaccine is  
11 administered concomitantly with other injectable vaccines, the vaccines should be administered  
12 with different syringes and given at separate injection sites.

13

## 14 **7.2 Immunosuppressive Therapies**

15 Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic  
16 drugs, and corticosteroids (used in greater than physiologic doses) may reduce the immune  
17 response to vaccines.

18

# 19 **8 USE IN SPECIFIC POPULATIONS**

## 20 **8.1 Pregnancy**

21 Pregnancy Category C

22 Animal reproduction studies have not been conducted with Menactra vaccine. It is also not known  
23 whether Menactra vaccine can cause fetal harm when administered to a pregnant woman or can

1 affect reproduction capacity. There are no adequate and well controlled studies in pregnant  
2 women. Menactra vaccine should only be given to a pregnant woman if clearly needed.  
3 Assessment of the effects on animal reproduction has not been fully conducted with Menactra  
4 vaccine as effects on male fertility in animals has not been evaluated. The effect of Menactra  
5 vaccine on embryo-fetal and pre-weaning development was evaluated in one developmental  
6 toxicity study in mice. Animals were administered Menactra vaccine on Day 14 prior to gestation  
7 and during the period of organogenesis (gestation Day 6). The total dose given per time point was  
8 0.1 mL/mouse via intramuscular injection (900 times the human dose, adjusted by body weight).  
9 There were no adverse effects on pregnancy, parturition, lactation or pre-weaning development  
10 noted in this study. Skeletal examinations revealed one fetus (1 of 234 examined) in the vaccine  
11 group with a cleft palate. None were observed in the concurrent control group (0 of 174  
12 examined). There are no data that suggest that this isolated finding is vaccine-related, and there  
13 were no vaccine-related fetal malformations or other evidence of teratogenesis observed in this  
14 study.

15

16 Healthcare providers are encouraged to register women who receive Menactra vaccine during  
17 pregnancy in Sanofi Pasteur Inc.'s vaccination pregnancy registry by calling 1-800-822-2463.

18

### 19 **8.3 Nursing Mothers**

20 It is not known whether Menactra vaccine is excreted in human milk. Because many drugs are  
21 excreted in human milk, caution should be exercised when Menactra vaccine is administered to a  
22 nursing woman.

23

1 **8.4 Pediatric Use**

2 Menactra vaccine is not approved for use in infants under 9 months of age. Available data show  
3 that infants administered three doses of Menactra vaccine (at 2, 4, and 6 months of age) had  
4 diminished responses to each meningococcal vaccine serogroup compared to older children given  
5 two doses at 9 and 12 months of age.

6  
7 **8.5 Geriatric Use**

8 Safety and effectiveness of Menactra vaccine in adults older than 55 years of age have not been  
9 established.

10

11 **11 DESCRIPTION**

12 Menactra®, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid  
13 Conjugate Vaccine, is a sterile, intramuscularly administered vaccine that contains *Neisseria*  
14 *meningitidis* serogroup A, C, Y and W-135 capsular polysaccharide antigens individually  
15 conjugated to diphtheria toxoid protein. *N meningitidis* A, C, Y and W-135 strains are cultured on  
16 Mueller Hinton agar (3) and grown in Watson Scherp (4) media containing casamino acid. The  
17 polysaccharides are extracted from the *N meningitidis* cells and purified by centrifugation,  
18 detergent precipitation, alcohol precipitation, solvent extraction and diafiltration. To prepare the  
19 polysaccharides for conjugation, they are depolymerized, derivatized, and purified by  
20 diafiltration. Diphtheria toxin is derived from *Corynebacterium diphtheriae* grown in modified  
21 culture medium containing hydrolyzed casein (5) and is detoxified using formaldehyde. The  
22 diphtheria toxoid protein is purified by ammonium sulfate fractionation and diafiltration. The  
23 derivatized polysaccharides are covalently linked to diphtheria toxoid and purified by serial

---

1 diafiltration. The four meningococcal components, present as individual serogroup-specific  
2 glycoconjugates, compose the final formulated vaccine. No preservative or adjuvant is added  
3 during manufacture. Each 0.5 mL dose may contain residual amounts of formaldehyde of less  
4 than 2.66 mcg (0.000532%), by calculation. Potency of Menactra vaccine is determined by  
5 quantifying the amount of each polysaccharide antigen that is conjugated to diphtheria toxoid  
6 protein and the amount of unconjugated polysaccharide present.

7

8 Menactra vaccine is manufactured as a sterile, clear to slightly turbid liquid. Each 0.5 mL dose of  
9 vaccine is formulated in sodium phosphate buffered isotonic sodium chloride solution to contain 4  
10 mcg each of meningococcal A, C, Y and W-135 polysaccharides conjugated to approximately 48  
11 mcg of diphtheria toxoid protein carrier.

12

13 The vial stopper is not made with natural rubber latex.

14

## 15 **12 CLINICAL PHARMACOLOGY**

### 16 **12.1 Mechanism of Action**

17 The presence of bactericidal anti-capsular meningococcal antibodies has been associated with  
18 protection from invasive meningococcal disease (6) (7). Menactra vaccine induces the production  
19 of bactericidal antibodies specific to the capsular polysaccharides of serogroups A, C, Y and W-  
20 135.

21

## 22 **13 NON-CLINICAL TOXICOLOGY**

### 23 **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

1 Menactra vaccine has not been evaluated for carcinogenic or mutagenic potential, or for  
2 impairment of fertility.

3

## 4 **14 CLINICAL STUDIES**

### 5 **14.1 Efficacy**

6 The serum bactericidal assay (SBA) used to test sera contained an exogenous complement source  
7 that was either human (SBA-H) or baby rabbit (SBA-BR). (8)

8

9 The response to vaccination following two doses of vaccine administered to children 9 and 12  
10 months of age and following one dose of vaccine administered to children 2 through 10 years of  
11 age was evaluated by the proportion of subjects having an SBA-H antibody titer of 1:8 or greater,  
12 for each serogroup. In individuals 11 through 55 years of age, the response to vaccination with a  
13 single dose of vaccine was evaluated by the proportion of subjects with a 4-fold or greater  
14 increase in bactericidal antibody to each serogroup as measured by SBA-BR. For individuals 2  
15 through 55 years of age, vaccine efficacy after a single dose was inferred from the demonstration  
16 of immunologic equivalence to a US-licensed meningococcal polysaccharide vaccine, Menomune  
17 – A/C/Y/W-135 vaccine as assessed by SBA.

18

### 19 **14.2 Immunogenicity**

#### 20 *Children 9 through 12 Months of Age*

21 In a randomized, US, multi-center trial, children received Menactra vaccine at 9 months and 12  
22 months of age. The first Menactra dose was administered alone, followed by a second Menactra  
23 vaccine dose given alone (N=404), or with MMRV (N=302), or with PCV7 (N=422). For all



1 participants, sera were obtained approximately 30 days after last vaccination. There were no  
2 substantive differences in demographic characteristics between the vaccine groups. The median  
3 age range for administration of the first dose of Menactra was 278-279 days of age.

4

5

1 **Table 5: Bactericidal Antibody Responses<sup>a</sup> 30 Days Following a Second Dose of Menactra**  
 2 **Vaccine Administered Alone or Concomitantly Administered with MMRV or PCV7**  
 3 **Vaccines at 12 Months of Age**

		Vaccinations administered at 12 months of age following a dose of Menactra at 9 months of age					
		Menactra vaccine		Menactra + MMRV vaccines		Menactra + PCV7 vaccines	
		(N=272-277) <sup>b</sup>		(N=177-180) <sup>b</sup>		(N=264-267) <sup>b</sup>	
Serogroup			(95% CI) <sup>c</sup>		(95% CI) <sup>c</sup>		(95% CI) <sup>c</sup>
<b>A</b>	% ≥1:8 <sup>d</sup>	95.6	(92.4; 97.7)	92.7	(87.8; 96.0)	90.5	(86.3; 93.8)
	GMT	54.9	(46.8; 64.5)	52.0	(41.8; 64.7)	41.0	(34.6; 48.5)
<b>C</b>	% ≥1:8 <sup>d</sup>	100.0	(98.7; 100.0)	98.9	(96.0; 99.9)	97.8	(95.2; 99.2)
	GMT	141.8	(123.5; 162.9)	161.9	(136.3; 192.3)	109.5	(94.1; 127.5)
<b>Y</b>	% ≥1:8 <sup>d</sup>	96.4	(93.4; 98.2)	96.6	(92.8; 98.8)	95.1	(91.8; 97.4)
	GMT	52.4	(45.4; 60.6)	60.2	(50.4; 71.7)	39.9	(34.4; 46.2)
<b>W-135</b>	% ≥1:8 <sup>d</sup>	86.4	(81.8; 90.3)	88.2	(82.5; 92.5)	81.2	(76.0; 85.7)
	GMT	24.3	(20.8; 28.3)	27.9	(22.7; 34.3)	17.9	(15.2; 21.0)

4 <sup>a</sup> Serum bactericidal assay with an exogenous human complement (SBA-H) source.

5 <sup>b</sup> N=Number of participants with at least one valid serology result from a blood sample obtained between Days 30 to  
 6 44 post vaccination.

7 <sup>c</sup> 95% CIs for the proportions are calculated based on the Clopper-Pearson Exact method and normal approximation  
 8 for that of the GMTs.

1 <sup>d</sup> The proportion of participants achieving an SBA-H titer of at least 1:8 thirty days after the second dose of Menactra  
2 vaccine.

3

4 Administration of Menactra to children at 12 months and 15 months of age was evaluated in a US  
5 study. Prior to the first dose, 33.3% [n=16/48] of participants had an SBA-H titer  $\geq$ 1:8 to  
6 Serogroup A, and 0-2% [n=0-1 of 50-51] to Serogroups C, Y and W-135. After the second dose,  
7 percentages of participants with an SBA-H titer  $\geq$ 1:8 were: 85.2%, Serogroup A [n=46/54];  
8 100.0%, Serogroup C [n=54/54]; 96.3%, Serogroup Y [n=52/54]; 96.2%, Serogroup W-135  
9 [n=50/52].

10

#### 11 ***Individuals 2 through 55 Years of Age***

12 Immunogenicity was evaluated in three comparative, randomized, US, multi-center, active  
13 controlled clinical trials that enrolled children (2 through 10 years of age), adolescents (11  
14 through 18 years of age), and adults (18 through 55 years of age). Participants received a single  
15 dose of Menactra vaccine (N=2526) or Menomune – A/C/Y/W-135 vaccine (N=2317). For all age  
16 groups studied, sera were obtained before and approximately 28 days after vaccination. [Blinding  
17 procedures for safety assessments are described in *Adverse Reactions* (6).]

18

19 In each of the trials, there were no substantive differences in demographic characteristics between  
20 the vaccine groups, between immunogenicity subsets or the overall study population. In the study  
21 of children 2 through 10 years of age, the median age of participants was 3 years; 95% completed  
22 the study. In the adolescent trial, the median age for both groups was 14 years; 99% completed the  
23 study. In the adult trial, the median age for both groups was 24 years; 94% completed the study.

1  
 2  
 3  
 4  
 5  
 6  
 7

**Immunogenicity in Children 2 through 10 Years of Age**

Of 1408 enrolled children 2 through 10 years of age, immune responses evaluated in a subset of Menactra vaccine participants (2 through 3 years of age, n=52; 4-10 years of age, n=84) and Menomune – A/C/Y/W-135 vaccine participants (2 through 3 years of age, n=53; 4-10 years of age, n=84) were comparable for all four serogroups (Table 6).

8 **Table 6: Comparison of Bactericidal Antibody Responses<sup>a</sup> to Menactra Vaccine and**  
 9 **Menomune – A/C/Y/W-135 Vaccine 28 Days after Vaccination for a Subset of Participants 2**  
 10 **through 3 Years of Age and 4 through 10 Years of Age**

		Ages 2 through 3 Years				Ages 4 through 10 Years			
		Menactra vaccine		Menomune – A/C/Y/W-135 vaccine		Menactra vaccine		Menomune – A/C/Y/W-135 vaccine	
		N <sup>b</sup> =48-52		N <sup>b</sup> =50-53		N <sup>b</sup> =84		N <sup>b</sup> =84	
Serogroup			(95% CI) <sup>c</sup>		(95% CI) <sup>c</sup>		(95% CI) <sup>c</sup>		(95% CI) <sup>c</sup>
A	% ≥1:8 <sup>d</sup>	73	(59,84)	64	(50,77)	81	(71,89)	55	(44,66)
	GMT	10	(8,13)	10	(7,12)	19	(14,26)	7	(6,9)
C	% ≥1:8 <sup>d</sup>	63	(48,76)	38	(25,53)	79	(68,87)	48	(37,59)
	GMT	27	(14,52)	11	(5,21)	28	(19,41)	12	(7,18)
Y	% ≥1:8 <sup>d</sup>	88	(75,95)	73	(59,84)	99	(94,100)	92	(84,97)
	GMT	51	(31,84)	18	(11,27)	99	(75,132)	46	(33,66)
W-135	% ≥1:8 <sup>d</sup>	63	(47,76)	33	(20,47)	85	(75,92)	79	(68,87)
	GMT	15	(9,25)	5	(3,6)	24	(18,33)	20	(14,27)

1 <sup>a</sup> Serum bactericidal assay with an exogenous human complement (SBA-H) source.

2 <sup>b</sup> N=Number of subset participants with at least one valid serology result at Day 0 and Day 28.

3 <sup>c</sup> The 95% CI for the Geometric Mean Titer (GMT) was calculated based on an approximation to the normal  
4 distribution.

5 <sup>d</sup> The proportion of participants achieving an SBA-H titer of at least 1:8 was assessed using a 10% non-inferiority  
6 margin and a one-sided Type 1 error rate of 0.025.

7

8 In the subset of participants 2 through 3 years of age with undetectable pre-vaccination titers  
9 (ie, SBA-H titers <1:4 at Day 0), seroconversion rates (defined as the proportions of participants  
10 with SBA-H titers  $\geq$ 1:8 by Day 28) were similar between the Menactra vaccine and Menomune –  
11 A/C/Y/W-135 vaccine recipients. Menactra vaccine participants achieved seroconversion rates of:  
12 57%, Serogroup A (n=12/21); 62%, Serogroup C (n=29/47); 84%, Serogroup Y (n=26/31); 53%,  
13 Serogroup W-135 (n=20/38). The seroconversion rates for Menomune – A/C/Y/W-135 vaccine  
14 recipients were: 55%, Serogroup A (n=16/29); 30%, Serogroup C (n=13/43); 57%, Serogroup Y  
15 (n=17/30); 26%, Serogroup W-135 (n=11/43).

16

17 In the subset of participants 4 through 10 years of age with undetectable pre-vaccination titers  
18 (ie, SBA-H titers <1:4 at Day 0), seroconversion rates (defined as the proportions of participants  
19 with SBA-H titers  $\geq$ 1:8 by Day 28) were similar between the Menactra vaccine and Menomune –  
20 A/C/Y/W-135 vaccine recipients. Menactra vaccine participants achieved seroconversion rates of:  
21 69%, Serogroup A (n=11/16); 81%, Serogroup C (n=50/62); 98%, Serogroup Y (n=45/46); 69%,  
22 Serogroup W-135 (n=27/39). The seroconversion rates for Menomune – A/C/Y/W-135 vaccine  
23 recipients were: 48%, Serogroup A (n=10/21); 38%, Serogroup C (n=19/50); 84%, Serogroup Y  
24 (n=38/45); 68%, Serogroup W-135 (n=26/38).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

***Immunogenicity in Adolescents 11 through 18 Years of Age***

Results from the comparative clinical trial conducted in 881 adolescents aged 11 through 18 years showed that the immune responses to Menactra vaccine and Menomune – A/C/Y/W-135 vaccine were similar for all four serogroups (Table 7).

In participants with undetectable pre-vaccination titers (ie, SBA-BR titers <1:8 at Day 0), seroconversion rates (defined as the proportions of participants achieving a  $\geq 4$ -fold rise in SBA-BR titers by Day 28) were similar between the Menactra vaccine and Menomune – A/C/Y/W-135 vaccine recipients. Menactra vaccine participants achieved seroconversion rates of: 100%, Serogroup A (n=81/81); 99%, Serogroup C (n=153/155); 98%, Serogroup Y (n=60/61); 99%, Serogroup W-135 (n=161/164). The seroconversion rates for Menomune – A/C/Y/W-135 vaccine recipients were: 100%, Serogroup A (n=93/93); 99%, Serogroup C (n=151/152); 100%, Serogroup Y (n=47/47); 99%, Serogroup W-135 (n=138/139).

***Immunogenicity in Adults 18 through 55 Years of Age***

Results from the comparative clinical trial conducted in 2554 adults aged 18 through 55 years showed that the immune responses to Menactra vaccine and Menomune – A/C/Y/W-135 vaccine were similar for all four serogroups (Table 7).

1 **Table 7: Comparison of Bactericidal Antibody Responses<sup>a</sup> to Menactra Vaccine and**  
2 **Menomune – A/C/Y/W-135 Vaccine 28 Days after Vaccination for Participants 11 through**  
3 **18 Years of Age and 18 through 55 Years of Age**

		Ages 11 through 18 Years				Ages 18 through 55 Years			
		Menactra vaccine		Menomune – A/C/Y/W-135 vaccine		Menactra vaccine		Menomune – A/C/Y/W-135 vaccine	
		N <sup>b</sup> =423		N <sup>b</sup> =423		N <sup>b</sup> =1280		N <sup>b</sup> =1098	
Serogroup			(95% CI) <sup>c</sup>		(95% CI) <sup>c</sup>		(95% CI) <sup>c</sup>		(95% CI) <sup>c</sup>
<b>A</b>	% ≥4-fold rise <sup>d</sup>	92.7	(89.8, 95.0)	92.4	(89.5, 94.8)	80.5	(78.2, 82.6)	84.6	(82.3, 86.7)
	GMT	5483	(4920, 6111)	3246	(2910, 3620)	3897	(3647, 4164)	4114	(3832, 4417)
<b>C</b>	% ≥4-fold rise <sup>d</sup>	91.7	(88.7, 94.2)	88.7	(85.2, 91.5)	88.5	(86.6, 90.2)	89.7	(87.8, 91.4)
	GMT	1924	(1662, 2228)	1639	(1406, 1911)	3231	(2955, 3533)	3469	(3148, 3823)
<b>Y</b>	% ≥4-fold rise <sup>d</sup>	81.8	(77.8, 85.4)	80.1	(76.0, 83.8)	73.5	(71.0, 75.9)	79.4	(76.9, 81.8)
	GMT	1322	(1162, 1505)	1228	(1088, 1386)	1750	(1597, 1918)	2449	(2237, 2680)
<b>W-135</b>	% ≥4-fold rise <sup>d</sup>	96.7	(94.5, 98.2)	95.3	(92.8, 97.1)	89.4	(87.6, 91.0)	94.4	(92.8, 95.6)
	GMT	1407	(1232, 1607)	1545	(1384, 1725)	1271	(1172, 1378)	1871	(1723, 2032)

4 <sup>a</sup> Serum bactericidal assay with baby rabbit complement (SBA-BR).

5 <sup>b</sup> N=Number of subset participants with at least one valid serology result at Day 0 and Day 28.

6 <sup>c</sup> The 95% CI for the Geometric Mean Titer (GMT) was calculated based on an approximation to the normal  
7 distribution.

8 <sup>d</sup> Menactra vaccine was non-inferior to Menomune – A/C/Y/W-135 vaccine. Non-inferiority was assessed by the  
9 proportion of participants with a 4-fold or greater rise in SBA-BR titer for *N meningitidis* serogroups A, C, Y and  
10 W-135 using a 10% non-inferiority margin and a one-sided Type I error rate of 0.05.

1  
2 In participants with undetectable pre-vaccination titers (ie, SBA-BR titers <1:8 at Day 0),  
3 seroconversion rates (defined as the proportions of participants achieving a  $\geq 4$ -fold rise in SBA-  
4 BR titers by Day 28) were similar between the Menactra vaccine and Menomune – A/C/Y/W-135  
5 vaccine recipients. Menactra vaccine participants achieved seroconversion rates of: 100%,  
6 Serogroup A (n=156/156); 99%, Serogroup C (n=343/345); 91%, Serogroup Y (n=253/279);  
7 97%, Serogroup W-135 (n=360/373). The seroconversion rates for Menomune – A/C/Y/W-135  
8 vaccine recipients were: 99%, Serogroup A (n=143/144); 98%, Serogroup C (n=297/304); 97%,  
9 Serogroup Y (n=221/228); 99%, Serogroup W-135 (n=325/328).

10

### 11 ***Immunogenicity in Adolescents and Adults Following Booster Vaccination***

12 [For a description of the study design and number of participants, see *Clinical Trials Experience,*  
13 *Booster Vaccination Study (6.1).*] Prior to revaccination, the percentage of subjects (n=781) with  
14 an SBA-H titer  $\geq 1:8$  were 64.5%, 44.2%, 38.7%, and 68.5% for Serogroups A, C, Y, and W-135,  
15 respectively. Among the subset of trial participants (n=112) for whom SBA-H responses at Day 6  
16 were assessed, 86.6%, 91.1%, 94.6%, and 92.0% achieved a  $\geq 4$ -fold rise in SBA-H titer for  
17 Serogroups A, C, Y, and W-135, respectively. The proportions of participants (n=781) who  
18 achieved a  $\geq 4$ -fold rise in SBA-H titer by Day 28 were 95.0%, 95.3%, 97.1%, and 96% for  
19 Serogroups A, C, Y, and W-135, respectively. The proportions of participants who achieved an  
20 SBA-H titer  $\geq 1:8$  by Day 28 were >99% for each serogroup.

21

### 22 **14.3 Concomitant Vaccine Administration**



1 ***MMRV (or MMR+V) or PCV7***

2 In a US, active-controlled trial, 1179 children received Menactra vaccine at 9 months and 12  
3 months of age. At 12 months of age these children received Menactra concomitantly with MMRV  
4 (N=616), or MMR+V (N=48), or PCV7 (N=250). Another group of 12-month old children  
5 received MMRV+PCV7 (N=485). Sera were obtained approximately 30 days after the last  
6 vaccinations. Measles, mumps, rubella and varicella antibody responses among children who  
7 received Menactra vaccine and MMRV (or MMR and V) were comparable to corresponding  
8 antibody responses among children who received MMRV and PCV7.

9

10 When Menactra was given concomitantly with PCV7, the non-inferiority criteria for comparisons  
11 of pneumococcal IgG GMCs (upper limit of the two-sided 95% CI of the GMC ratio  $\leq 2$ ) were not  
12 met for 3 of 7 serotypes (4, 6B, 18C). In a subset of subjects with available sera, pneumococcal  
13 opsonophagocytic assay GMT data were consistent with IgG GMC data.

14

15 ***Td***

16 In a double-blind, randomized, controlled trial, 1021 participants aged 11 through 17 years  
17 received Td and Menactra vaccines concomitantly (N=509), or Td followed one month later by  
18 Menactra vaccine (N=512). Sera were obtained approximately 28 days after each respective  
19 vaccination. The proportions of participants with a 4-fold or greater increase in SBA-BR titer to  
20 meningococcal Serogroups C, Y and W-135 were higher when Menactra vaccine was given  
21 concomitantly with Td (86-96%) than when Menactra vaccine was given one month following Td  
22 (65-91%). Anti-tetanus and anti-diphtheria antibody responses were similar in both study groups.

23

1 *Typhim Vi*

2 In a double-blind, randomized, controlled trial, 945 participants aged 18 through 55 years  
3 received Typhim Vi and Menactra vaccines concomitantly (N=469), or Typhim Vi vaccine  
4 followed one month later by Menactra vaccine (N=476). Sera were obtained approximately 28  
5 days after each respective vaccination. The antibody responses to Menactra vaccine and to  
6 Typhim Vi vaccine components were similar in both study groups.

7

8

## 15 REFERENCES

- 1 CDC. Guillain-Barré syndrome among recipients of Menactra® meningococcal conjugate  
2 vaccine-United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep  
3 2006;55:1120-1124. Erratum in: MMWR Morb Mortal Wkly Rep 2006;55(43):1177.
- 4 Harvard Medical School/Harvard Pilgrim Health Care Institute. Risk of Guillain-Barré  
5 Syndrome Following Meningococcal Conjugate (MCV4) Vaccination. Final Study Report,  
6 Revised March 11, 2010.
- 7 Mueller JH, et al. A protein-free medium for primary isolation of the gonococcus and  
8 meningococcus. Proc Soc Exp Biol Med 1941;48:330-333.
- 9 Watson RG, et al. The specific haptens of group C (group IIa) meningococcus. I. Preparation  
10 and immunological behavior. J Immunol 1958;81:331-336.
- 11 Mueller JH, et al. Production of diphtheria toxin of high potency (100 Lf) on a reproducible  
12 medium. J Immunol 1941;40:21-32.
- 13 Mäkelä PH, et al. Evolution of conjugate vaccines. Expert Rev Vaccines 2002;1:399-410.
- 14 Goldschneider I, et al. Human immunity to the meningococcus. I. The role of humoral  
15 antibodies. J Exp Med 1969;129:1307-1326.
- 16 Maslanka SE, et al. Standardization and a multilaboratory comparison of Neisseria  
17 meningitidis serogroup A and C serum bactericidal assays. Clin and Diag Lab Immunol  
18 1997;4:156-167.

---

## 16 HOW SUPPLIED/STORAGE AND HANDLING

### 16.1 How Supplied

- Single-dose vial, 0.5 mL (NDC 49281-589-58). Supplied as a package of 5 vials (NDC 49281-589-05).

### 16.2 Storage and Handling

Store at 2° to 8°C (35° to 46°F). DO NOT FREEZE. Frozen/previously frozen product should not be used. Do not use after the expiration date.

## 17 PATIENT COUNSELING INFORMATION

Vaccine Information Statements are required by the National Childhood Vaccine Injury Act of 1986 to be given prior to immunization to the patient, parent, or guardian. These materials are available free of charge at the Centers for Disease Control and Prevention (CDC) website ([www.cdc.gov/vaccines](http://www.cdc.gov/vaccines).)

Inform the patients, parents or guardians about:

- Potential benefits and risks of immunization with Menactra vaccine.
- Potential for adverse reactions that have been temporally associated with administration of Menactra vaccine or other vaccines containing similar components.
- Reporting any adverse reactions to their healthcare provider.
- The Sanofi Pasteur Inc. Pregnancy Registry, as appropriate.

Menactra vaccine is a registered trademark of Sanofi Pasteur Inc.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

Manufactured by:

**Sanofi Pasteur Inc.**

Swiftwater PA 18370 USA

6463

